Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Optimi HealthFRA:8BN0 +0.65%35 PS Ratio is 84.13 as of Jul. 14, 2026, which is 9% below its 10-year median of 92.29. GuruFocus rates FRA:8BN0 with a GF Score™ of 35/100 and a GF Value™ of €3.51 (Fairly Valued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Optimi Health ranks worse than 97.7% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Optimi Health's share price is €3.87.
Optimi Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.05. Hence, Optimi Health's PS Ratio for today is 84.13.
The historical rank and industry rank for Optimi Health's PS Ratio or its related term are showing as below:
FRA:8BN0'
s PS Ratio Range Over the Past 10 Years
Min: 24.56 Med: 92.29 Max: 4000
Current: 90.14
During the past 6 years, Optimi Health's highest PS Ratio was 4000.00. The lowest was 24.56. And the median was 92.29.
FRA:8BN0's PS Ratio is ranked worse than 97.7% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs FRA:8BN0: 90.14
During the past 12 months, the average Revenue per Share Growth Rate of Optimi Health was -52.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 62.50% per year.
During the past 6 years, Optimi Health's highest 3-Year average Revenue per Share Growth Rate was 62.50% per year. The lowest was 62.50% per year. And the median was 62.50% per year.
Back to Basics: PS Ratio
Optimi Health (FRA:8BN0) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Optimi Health PS Ratio Related Terms
Optimi Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Optimi Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Optimi Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Optimi Health PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Optimi Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Optimi Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Optimi Health's Share Price of today is €3.87. Optimi Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Optimi Health (FRA:8BN0) has a PS Ratio of 84.13 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Optimi Health and its competitors. This is near median its historical median of 92.29. Over the past decade, Optimi Health's PS Ratio has ranged from 24.56 to 4,000.00. According to the industry distribution chart, Optimi Health ranks #933 out of 955 companies in the Drug Manufacturers industry, placing it in the top 97.7%.
Is Optimi Health's PS Ratio too high?
Optimi Health's current PS Ratio of 84.13 is near median its 10-year median of 92.29. Over the past 10 years, this metric has ranged from a low of 24.56 to a high of 4,000.00. The Drug Manufacturers industry median PS Ratio is 2.33. Optimi Health's value of 84.13 is 3510.7% above this industry median. Based on the distribution chart, Optimi Health ranks #933 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Optimi Health has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Optimi Health's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Optimi Health ranks #933 out of 955 companies for PS Ratio. This places Optimi Health in the lower half of its industry. The industry median PS Ratio is 2.33. Optimi Health's value of 84.13 is 3510.7% above this benchmark. Historically, Optimi Health's own PS Ratio has ranged from 24.56 to 4,000.00 over the past decade. While the company's 10-year median is 92.29 vs. the industry median of 2.33, Optimi Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Optimi Health's current PS Ratio of 84.13 is 3510.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Optimi Health and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Optimi Health's current PS Ratio is 84.13, which is near median its own 10-year median of 92.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optimi Health stock overvalued right now?
Based on GuruFocus' analysis, Optimi Health (FRA:8BN0) is currently considered Fairly Valued. The stock's GF Value™ is €3.51, compared to a current price of €3.87 — trading 10.3% above its estimated fair value. The current PS Ratio is 84.13, which is near median its 10-year median of 92.29 and 3510.7% above the Drug Manufacturers industry median of 2.33. Optimi Health's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Optimi Health (FRA:8BN0), the current PS Ratio is 84.13 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Optimi Health (FRA:8BN0) Overvalued in 2026?
Based on GuruFocus' analysis, Optimi Health stock appears to be overvalued.
The current stock price of €3.87 is trading 10.3% above its estimated GF Value™ of €3.51.
GuruFocus considers Optimi Health to be Fairly Valued.
Key valuation signals for FRA:8BN0:
PS Ratio: 84.13 (near median its 10-year median of 92.29)
GF Value™: €3.51 vs. price of €3.87 (10.3% above fair value)
Industry Position: 3510.7% above the Drug Manufacturers median (#933 of 955)
No single metric tells the full story. See the FRA:8BN0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
35GF Score
Get the complete analysis for FRA:8BN0
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8BN0 has been successfully added to your 
